NeuroPace, Inc. (NPCE)

NGM – Цена в реальном времени. Валюта: USD

16.47

+0.11 (0.67%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

16.47

-0.00 (-0.00%)

После закрытия: Jun 26, 2026, 4:31 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

NeuroPace, Inc. (NPCE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NeuroPace, Inc. (NPCE)

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade

NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?

Here's Why You Should Add NeuroPace Stock to Your Portfolio Now

NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?

Видео

No Data

Пресс-релизы

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

Search stocks

NeuroPace, Inc. (NPCE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

NeuroPace, Inc. (NPCE)

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade

NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?

Here's Why You Should Add NeuroPace Stock to Your Portfolio Now

NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?

Видео

No Data

Пресс-релизы

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026